GlobeNewswire by notified

Anmodning om suspension i afdelinger under Investeringsforeningen Danske Invest

1.5.2024 09:00:47 CEST | GlobeNewswire by notified

Del
Nasdaq Copenhagen
Nikolaj Plads 6
1007 København K







Parallelvej 17
2800 Kgs. Lyngby
Telefon 33 33 71 71
Telefax 33 15 71 71
www.danskeinvest.dk

Anmodning om suspension i afdelinger under Investeringsforeningen Danske Invest

Grundet lokal børslukkedag i de underliggende markeder anmodes om suspension i nedenstående afdelinger/andelsklasser under Investeringsforeningen Danske Invest den 1. maj 2024.

Investeringsforeningen Danske Invest:

Afdeling/andelsklasseISIN-kode OMX Identifikation
Europa - Akkumulerende, klasse DKK hDK0016290265DKIEUADKKH
Europa 2 KLDK0010245901DKIEU2KL
Europa Højt Udbytte - Akkumulerende, klasse DKKDK0060058618DKIEUHUAKLDKK
Europa Højt Udbytte, klasse DKK dDK0016253651DKIEAUHU
Europa Indeks BNP, klasse DKK dDK0015737563DKIEUIXBNP
Europa Indeks, klasse DKK dDK0010266311DKIEUIX
Europa, klasse DKK dDK0010252956DKIEU
Europa Small Cap - Akkumulerende, klasse DKKDK0060640191DKIEUSCADKK
Europa Small Cap, klasse DKK dDK0060046019DKIEUSC
Fjernøsten Indeks, klasse DKK dDK0010207141DKIFJIX
Fjernøsten, klasse DKK dDK0015966758DKIFJE
Kina, klasse DKK dDK0010295336DKIKI
Nye Markeder - Akkumulerende, klasse DKKDK0060042026DKINMAKK
Nye Markeder, klasse DKK dDK0015710602DKINYM
Nye Markeder Small Cap, klasse DKK dDK0060080380DKINMSC

Med venlig hilsen

DANSKE INVEST
MANAGEMENT A/S

Tina Hjorth Hetting

Head of Fund Products

For at se dette indhold fra www.globenewswire.com, så skal du give din accept på toppen af denne side.
For at se dette indhold fra ml-eu.globenewswire.com, så skal du give din accept på toppen af denne side.

Information om GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg pressemeddelelser fra GlobeNewswire by notified

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra GlobeNewswire by notified

Duck Creek Technologies Highlights Esteemed Sponsors of Formation '2421.5.2024 14:30:00 CEST | Press release

Formation ‘24 - The Pinnacle Gathering of Global Insurance and Technology Innovators – Features Dozens of Industry Sponsors. BOSTON, May 21, 2024 (GLOBE NEWSWIRE) -- Duck Creek Technologies, the intelligent solutions provider defining the future of property and casualty (P&C) and general insurance, is thrilled to unveil the prominent sponsors set to join the forefront of insurance technology decision-makers at its highly anticipated customer conference, Formation ’24. The event is scheduled to take place from May 21 to May 23, 2024, at the Omni Dallas Hotel in Dallas, Texas. Duck Creek is poised to welcome insurtech leaders and industry professionals from around the world, fostering a dynamic environment with abundant educational and networking prospects centered on the latest trends and innovations driving the insurance industry forward. “This year we have record sponsorship commitments from over 60 members of our partner ecosystem, including platinum sponsors Aggne Global, Coforge, C

Ketabon To Present Advancements In At-Home Ketamine Therapy For Treatment-Resistant Depression At American Society Of Clinical Psychopharmacology Annual Meeting21.5.2024 14:30:00 CEST | Press release

Presentations Will Address Phase 2 Trial Success With Lead Asset KET01 And Comparative Study With Intranasal SPRAVATO® MUNICH, Germany, May 21, 2024 (GLOBE NEWSWIRE) -- Ketabon GmbH (“Ketabon” or “the Company”), a joint venture between HMNC Brain Health and Develco Pharma, announced today the Company will present poster presentations at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting taking place on May 28-31, 2024 at Miami Beach. Dr. Hans Eriksson, Chief Medical Officer of Ketabon and HMNC Brain Health, will elucidate details on topline results of its Phase 2 trial with KET01, an oral ketamine treatment with minimal side effects, showing rapid improvements in depression severity and Ketabon’s comparative study between KET01 and intranasal SPRAVATO®, the current FDA-approved ketamine formulation. Presentation details are as follows: Session: W16 Poster: Comparison of Tolerability, Safety, and Pharmacokinetics of Antidepressant Doses of Oral Ketamine Prolonged

HiddenA line styled icon from Orion Icon Library.Eye